secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001628280-22-003658
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

COMPASS Pathways reports FY2021 net loss $71.7M; positive phase IIb TRD results, FDA meeting in April
--------------------------------------------------------------------------------

- Net loss for FY2021 was $71.7M ($1.79 loss per share), vs $60.3M in FY2020; Q4 net loss $25.7M.
- Cash balance $273.2M at year-end 2021, up from $190.3M in 2020; well-capitalized for phase III.
- Positive phase IIb trial of COMP360 psilocybin for TRD: rapid and sustained response at 25mg dose.
- End-of-phase II meeting with FDA scheduled for late April 2022; phase III expected H2 2022.
- New senior executives: Dr Guy Goodwin (CMO), Mike Falvey (CFO), Matt Owens (General Counsel).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000162828022003658/0001628280-22-003658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000162828022003658/cmps-20220224.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-003658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer